Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Ovarian Neoplasms 1Lymphoma, Mantle-Cell 1Lymphoma 1Leukemia, B-Cell 1Leukemia 1Klatskin Tumor 1Hematologic Neoplasms 1Fallopian Tube Neoplasms 1Cholangiocarcinoma 1Breast Neoplasms 1Bile Duct Neoplasms 1

Interventions

Gemcitabine 24Cisplatin 14Capecitabine 12Oxaliplatin 11Fluorouracil 11Leucovorin 7Irinotecan 7Radiotherapy 5durvalumab 4Photochemotherapy 3Magnetic Resonance Spectroscopy 3Long-Term Synaptic Depression 3Erlotinib Hydrochloride 3Cholangiopancreatography, Endoscopic Retrograde 3Carboplatin 3trifluridine tipiracil drug combination 2regorafenib 2olaparib 2ceralasertib 2Stents 2Sorafenib 2Radiosurgery 2Radiofrequency Ablation 2Liver Transplantation 2Filgrastim 2Dihematoporphyrin Ether 21-phenyl-3,3-dimethyltriazene 2zimberelimab 1tivozanib 1titanium silicide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Bile Duct Neoplasms × ricolinostat × Clear all
NCT02856568 2017-05-30

Ricolinostat, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable or Metastatic Cholangiocarcinoma

Mayo Clinic

Phase 1 Withdrawn
Gastrointestinal

Bile Duct Neoplasms, Cholangiocarcinoma, Klatskin Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡